Licensing Deals &
Cross-Border Collaboration

For Chinese biotech and pharmaceutical companies seeking to license their assets to US and global partners, BioRich provides unparalleled access and advocacy. We do not simply make introductions — we build the case for your asset and maintain momentum through every stage of the process.

• Access to 250+ Chinese biotech clients with 400+ projects across all major therapeutic areas
• Small molecules, large molecules, ADCs, cell & gene therapies, and platform technologies
• Pre-screened deal packages: IP summary, clinical data, regulatory status, and valuation rationale
• Warm introductions to BD&L leadership at 25+ multinational pharmaceutical companies
• Deal structuring guidance: upfront, milestones, royalties, territory, and field-of-use optimization
• Post-term-sheet support through due diligence and execution

For US and global companies seeking to in-license Chinese assets, BioRich provides curated access to a pipeline that is largely invisible through conventional channels. We identify, assess, and facilitate — reducing the time and cost of China-sourced deal origination significantly.

• Curated identification of Chinese assets matching your therapeutic area and stage criteria
• Direct relationships with Chinese biotech leadership and BD teams
• Cultural and scientific translation: helping US partners understand China clinical data packages
• Regulatory strategy assessment for assets with China-only clinical packages
• Competitive landscape analysis for the specific indication and modality
• Facilitation of site visits and due diligence in China